Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Melanoma
Investigational mRNA-Based Vaccine May Offer New Hope for Patients With High-Risk Melanoma
By
Phoebe Starr
Emerging Therapies
,
Melanoma
,
Skin Cancer
,
AACR 2023 Annual Meeting
June 2023, Vol 14, No 3 - Online Only
During the 2023 American Association for Cancer Research Annual Meeting, researchers presented results from a phase 2b clinical trial demonstrating significant improvement in recurrence-free survival in patients with high-risk melanoma who were treated with a combination of an investigational personalized mRNA-based vaccine plus the immune checkpoint inhibitor pembrolizumab (Keytruda), compared with pembrolizumab alone.
Read Article
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
By
Wayne Kuznar
ASCO 2021 Highlights
,
Melanoma
August 2021, Vol 12, No 4
The addition of the lymphocyte activation gene-3 (
LAG-3
)–blocking antibody relatlimab to nivolumab (Opdivo) led to significantly longer progression-free survival (PFS) compared with nivolumab alone in previously untreated patients with advanced melanoma, according to results of the phase 3 RELATIVITY-047 clinical trial presented at the ASCO 2021 virtual annual meeting.
Read Article
Adjuvant Immunotherapy with Ipilimumab Improves Survival in Patients with Stage III Melanoma in the Real-World Setting
By
Phoebe Starr
Melanoma
October 2020, Vol 11, No 5
A real-world analysis showed that adjuvant immunotherapy in patients with stage III melanoma improved survival, but that only approximately 33% of eligible patients received such adjuvant therapy after ipilimumab (Yervoy) was approved by the FDA for this indication.
Read Article
Personalized Neoadjuvant Immunotherapy Combinations Improve Outcomes in Stage III Melanoma
By
Wayne Kuznar
Melanoma
June 2019, Vol 10, No 3
San Francisco, CA—Moving combination immunotherapy into the neoadjuvant setting for patients with stage III melanoma induces a higher rate of pathologic response than adjuvant therapy, said Christian U. Blank, MD, PhD, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Read Article
HF10 plus Ipilimumab Increases Response Rates in Metastatic Melanoma
By
Walter Alexander
Melanoma
,
Solid Tumors
September 2016, Vol 7, No 8
When combined with systemic ipilimumab (Yervoy), the investigational oncolytic viral immunotherapy HF10, a mutation of the HF strain of the herpes simplex virus type 1 (HSV-1), has local and systemic activity in patients with metastatic melanoma, said Robert Andtbacka, MD, CM, Huntsman Cancer Institute, Salt Lake City, during a poster presentation at the 2016 American Society of Clinical Oncology meeting. He added that HF10 substantially improves the response rate of ipilimumab alone and does not exacerbate ipilimumab toxicity.
Read Article
Combination Immunotherapy Makes Progress in Advanced Melanoma
By
Phoebe Starr
Melanoma
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Evidence is mounting that 2 immunotherapies are better than 1 as first-line treatment of patients with advanced melanoma. A phase 3 clinical trial showed that nivolumab plus ipilimumab was superior to ipilimumab or nivolumab alone, and a phase 1 trial suggests that pembrolizumab can be safely and effectively used in combination with other drugs as first-line treatment in this setting. Both studies were presented at ASCO 2016.
Read Article
Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma
By
Wayne Kuznar
Melanoma
,
Solid Tumors
June 2016, Vol 7, No 5
More than 33% of patients with heavily pretreated advanced melanoma are still alive at 5 years after starting nivolumab (Opdivo) monotherapy, reported F. Stephen Hodi, Jr, MD, Director of the Melanoma Center, Dana-Farber Cancer Institute, Boston, at the 2016 American Association for Cancer Research (AACR) meeting.
Read Article
Debating the Role of Intralesional Therapy in Melanoma
By
Walter Alexander
Melanoma
,
Solid Tumors
June 2016, Vol 7, No 5
“Intralesional therapy is here to stay,” said Sanjiv S. Agarwala, MD, Section Chief, Hematology/Oncology, St Luke’s University Health Network, Easton, PA, who moderated a debate on this topic at the recent
HemOnc Today
Melanoma and Cutaneous Malignancies meeting.
Read Article
Combination Immunotherapy the New Standard for Patients with Metastatic Melanoma
By
Walter Alexander
Melanoma
June 2016, Vol 7, No 5
Read Article
BRAF Protein Expression Potential New Marker for Mortality Risk in Melanoma
By
Rosemary Frei, MSc
Melanoma
September 2014, Vol 5, No 7
Toronto, Ontario—BRAF protein expression is correlated with melanoma progression and poor patient survival, according to recent studies that were reviewed at the 2014 Canadian Dermatology Association annual conference.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma